PE20170906A1 - Alfa-glucosidasa acida muy potente con hidratos de carbono potenciados - Google Patents
Alfa-glucosidasa acida muy potente con hidratos de carbono potenciadosInfo
- Publication number
- PE20170906A1 PE20170906A1 PE2017000507A PE2017000507A PE20170906A1 PE 20170906 A1 PE20170906 A1 PE 20170906A1 PE 2017000507 A PE2017000507 A PE 2017000507A PE 2017000507 A PE2017000507 A PE 2017000507A PE 20170906 A1 PE20170906 A1 PE 20170906A1
- Authority
- PE
- Peru
- Prior art keywords
- rhgaa
- glucosidase
- acid alpha
- enhanced carbon
- carbon hydrates
- Prior art date
Links
- 108010028144 alpha-Glucosidases Proteins 0.000 title abstract 2
- -1 CARBON HYDRATES Chemical class 0.000 title 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 229910052799 carbon Inorganic materials 0.000 title 1
- 230000003389 potentiating effect Effects 0.000 title 1
- 101001018026 Homo sapiens Lysosomal alpha-glucosidase Proteins 0.000 abstract 4
- 102000045921 human GAA Human genes 0.000 abstract 4
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 abstract 2
- 102100037182 Cation-independent mannose-6-phosphate receptor Human genes 0.000 abstract 1
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 abstract 1
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 abstract 1
- 206010053185 Glycogen storage disease type II Diseases 0.000 abstract 1
- 101001028831 Homo sapiens Cation-independent mannose-6-phosphate receptor Proteins 0.000 abstract 1
- VFRROHXSMXFLSN-KVTDHHQDSA-N aldehydo-D-mannose 6-phosphate Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O VFRROHXSMXFLSN-KVTDHHQDSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 201000004502 glycogen storage disease II Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UNA COMPOSICION DE ALFA GLUCOSIDASA HUMANA RECOMBINANTE (rhGAA) DERIVADA DE CELULAS CHO, DONDE LA rhGAA TIENE UNA SECUENCIA DE AMINOACIDOS QUE ES AL MENOS UN 95% IDENTICA A LA SEQ ID NO: 1; Y EN DONDE EL 50% O MAS DE LA rhGAA PRODUCIDA POR LAS CELULAS CHO SE UNE AL RECEPTOR DE MANOSA-6-FOSFATO CATION INDEPENDIENTE (CIMPR) O 50% O MAS DE DICHA rhGAA CONTIENE UN N-GLICANO QUE LLEVA MONO-MANOSA-6-FOSFATO (M6P) O BIS-M6P. TAMBIEN SE REFIERE A UN METODO PARA PRODUCIR DICHA COMPOSICION, LA CUAL ES UTIL EN EL TRATAMIENTO DE LA ENFERMEDAD DE POMPE
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462057847P | 2014-09-30 | 2014-09-30 | |
| US201462057842P | 2014-09-30 | 2014-09-30 | |
| US201562112463P | 2015-02-05 | 2015-02-05 | |
| US201562135345P | 2015-03-19 | 2015-03-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20170906A1 true PE20170906A1 (es) | 2017-07-12 |
Family
ID=55631441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017000507A PE20170906A1 (es) | 2014-09-30 | 2015-09-30 | Alfa-glucosidasa acida muy potente con hidratos de carbono potenciados |
Country Status (39)
| Country | Link |
|---|---|
| US (6) | US10208299B2 (es) |
| EP (3) | EP3201320B1 (es) |
| JP (3) | JP6851964B2 (es) |
| KR (4) | KR102455814B1 (es) |
| CN (2) | CN107075468B (es) |
| AU (3) | AU2015325028B2 (es) |
| BR (1) | BR112017005810A2 (es) |
| CA (2) | CA2961762C (es) |
| CL (1) | CL2017000722A1 (es) |
| CO (1) | CO2017002776A2 (es) |
| CR (1) | CR20170107A (es) |
| CY (2) | CY1126544T1 (es) |
| DK (2) | DK3201320T5 (es) |
| DO (1) | DOP2017000079A (es) |
| EA (1) | EA038986B1 (es) |
| EC (1) | ECSP17019103A (es) |
| ES (2) | ES2967620T3 (es) |
| FI (4) | FI3201320T3 (es) |
| FR (2) | FR24C1012I1 (es) |
| HR (2) | HRP20250058T1 (es) |
| HU (4) | HUE070443T2 (es) |
| IL (4) | IL289383B2 (es) |
| LT (4) | LT4273241T (es) |
| MX (2) | MX388241B (es) |
| MY (1) | MY186336A (es) |
| NI (1) | NI201700039A (es) |
| NO (1) | NO2025023I1 (es) |
| PE (1) | PE20170906A1 (es) |
| PH (1) | PH12017500455A1 (es) |
| PL (2) | PL4273241T3 (es) |
| PT (2) | PT3201320T (es) |
| RS (2) | RS65066B1 (es) |
| SG (2) | SG10202003753PA (es) |
| SI (2) | SI4273241T1 (es) |
| SM (2) | SMT202400010T1 (es) |
| SV (1) | SV2017005416A (es) |
| TN (1) | TN2017000082A1 (es) |
| WO (1) | WO2016054231A1 (es) |
| ZA (2) | ZA201701945B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2967620T3 (es) | 2014-09-30 | 2024-05-03 | Amicus Therapeutics Inc | Alfa-glucosidasa ácida altamente potente con carbohidratos potenciados |
| KR102510941B1 (ko) * | 2015-12-30 | 2023-03-20 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병 치료용의 강화된 산 알파-글루코시다제 |
| HRP20210894T1 (hr) * | 2015-12-30 | 2021-07-23 | Amicus Therapeutics, Inc. | Poboljšana kisela alfa-glukozidaza za liječenje pompeove bolesti |
| CN118581067A (zh) * | 2016-03-30 | 2024-09-03 | 阿米库斯治疗学公司 | 用于选择高m6p重组蛋白的方法 |
| IL319770A (en) | 2016-03-30 | 2025-05-01 | Amicus Therapeutics Inc | Method for selecting recombinant proteins with high mannose-6-phosphate content |
| KR102758570B1 (ko) | 2016-03-30 | 2025-01-23 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 재조합 산 알파-글루코시다제를 포함하는 제형 |
| JP2020503900A (ja) * | 2017-01-10 | 2020-02-06 | アミカス セラピューティックス インコーポレイテッド | ファブリー病の処置のための組換えアルファ−ガラクトシダーゼａ |
| EA039750B1 (ru) * | 2017-03-30 | 2022-03-10 | Амикус Терапьютикс, Инк. | Способ отбора рекомбинантных белков с высоким содержанием m6p |
| EP3624831B1 (en) * | 2017-05-15 | 2023-03-29 | Amicus Therapeutics, Inc. | Recombinant human acid alpha-glucosidase |
| WO2020028864A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| AU2020343680A1 (en) * | 2019-09-06 | 2022-03-24 | Amicus Therapeutics, Inc. | Method for capturing and purification of biologics |
| KR20230155622A (ko) * | 2021-02-11 | 2023-11-10 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 재조합 인간 산성 알파-글루코시다제 및 이의 용도 |
| WO2023150387A1 (en) * | 2022-02-07 | 2023-08-10 | M6P Therapeutics, Inc. | Compositions comprising acid alpha glucosidase and methods of use thereof |
| JP2025515159A (ja) | 2022-05-05 | 2025-05-13 | アミカス セラピューティックス インコーポレイテッド | ポンペ病の治療方法 |
| TW202436620A (zh) | 2022-12-02 | 2024-09-16 | 美商阿米庫斯醫療股份有限公司 | 用於在兒科患者中治療嬰兒型龐貝氏症之方法 |
| JP2025540119A (ja) | 2022-12-02 | 2025-12-11 | アミカス セラピューティックス インコーポレイテッド | 小児患者の遅発型ポンペ病の治療方法 |
| WO2026006625A1 (en) | 2024-06-26 | 2026-01-02 | Amicus Therapeutics, Inc. | Miglustat formulations comprising nitrosamine for use in the treatment of pompe disease |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4837237A (en) | 1985-07-09 | 1989-06-06 | Fred Hutchinson Cancer Research Center | Therapy using glucosidase processing inhibitors |
| US5879680A (en) | 1987-12-23 | 1999-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | Cloned DNA for synthesizing unique glucocerebrosidase |
| US4985445A (en) | 1988-02-12 | 1991-01-15 | Meiji Seika Kaisha, Ltd. | Cancer cell metastasis inhibitors and novel compounds |
| US6451600B1 (en) | 1989-12-22 | 2002-09-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| US5236838A (en) | 1988-12-23 | 1993-08-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| US5179023A (en) | 1989-03-24 | 1993-01-12 | Research Corporation Technologies, Inc. | Recombinant α-galactosidase a therapy for Fabry disease |
| US5011829A (en) | 1989-06-02 | 1991-04-30 | G. D. Searle & Co. | Pharmaceutical composition and method of inhibiting virus |
| US5103008A (en) | 1989-08-17 | 1992-04-07 | Monsanto Company | Compound, N-butyl-deoxynojirimycin-6-phosphate |
| US5401650A (en) | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| US5399567A (en) | 1993-05-13 | 1995-03-21 | Monsanto Company | Method of treating cholera |
| US6118045A (en) | 1995-08-02 | 2000-09-12 | Pharming B.V. | Lysosomal proteins produced in the milk of transgenic animals |
| US6458574B1 (en) | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
| US6083725A (en) | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
| US6210666B1 (en) | 1997-10-21 | 2001-04-03 | Orphan Medical, Inc. | Truncated α-galactosidase A to treat fabry disease |
| CA2309321A1 (en) | 1997-11-10 | 1999-05-20 | G.D. Searle & Co. | Use of alkylated iminosugars to treat multidrug resistance |
| US6465488B1 (en) | 1997-12-11 | 2002-10-15 | Chancellor, Masters & Scholars Of The University Of Oxford | Inhibition of glycolipid biosynthesis |
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| ATE410506T1 (de) | 1998-12-07 | 2008-10-15 | Genzyme Corp | Behandlung der pompeschen krankheit |
| CA2362914C (en) | 1999-02-12 | 2009-04-14 | G.D. Searle & Co. | Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections |
| CA2378776A1 (en) | 1999-07-26 | 2001-02-01 | G.D. Searle & Co. | Use of long-chain n-alkyl derivatives of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of medicament for the treatment of glycolipid storage diseases |
| US6537785B1 (en) | 1999-09-14 | 2003-03-25 | Genzyme Glycobiology Research Institute, Inc. | Methods of treating lysosomal storage diseases |
| WO2001097829A2 (en) | 2000-06-19 | 2001-12-27 | Genzyme Corporation | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US20040204379A1 (en) | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| TWI280882B (en) | 2000-07-18 | 2007-05-11 | Univ Duke | Composition for the treatment of glycogen storage disease type-II |
| CN1638739A (zh) | 2000-08-18 | 2005-07-13 | 法玛西雅厄普约翰美国公司 | 治疗成瘾性障碍的化合物 |
| US7723296B2 (en) * | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| WO2002087510A2 (en) | 2001-04-30 | 2002-11-07 | Symbiontics, Inc. | Subcellular targeting of therapeutic proteins |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| MXPA04003640A (es) | 2001-10-16 | 2005-04-11 | Rxkinetix Inc | Formulaciones de proteina de alta concentracion y metodo de fabricacion. |
| AU2003224880A1 (en) | 2002-04-05 | 2003-10-27 | Genzyme Corporation | Methods of enhancing lysosomal storage disease therapy |
| DK1589993T3 (en) | 2003-01-31 | 2015-03-09 | Sinai School Medicine | COMBINATION THERAPY FOR TREATMENT OF PROTEIN FAILURE DISORDERS |
| FR2861991B1 (fr) | 2003-11-07 | 2008-01-18 | Centre Nat Rech Scient | Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose |
| AU2005211775B2 (en) * | 2004-02-06 | 2009-10-08 | Biomarin Pharmaceutical Inc. | Manufacture of highly phosphorylated lysosomal enzymes and uses thereof |
| CA2553955C (en) | 2004-02-10 | 2012-08-28 | Zystor Therapeutics, Inc. | Acid alpha-glucosidase and fragments thereof |
| US20060142234A1 (en) | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
| CA2612538C (en) | 2005-05-17 | 2015-06-30 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
| CN101636200A (zh) * | 2006-11-13 | 2010-01-27 | 齐斯特治疗公司 | 用于治疗庞贝氏症的方法 |
| JP2010509344A (ja) | 2006-11-13 | 2010-03-25 | ザイストール セラピューティクス， インコーポレイテッド | ポンペ病を治療するための方法 |
| WO2008112525A2 (en) | 2007-03-09 | 2008-09-18 | Link Medicine Corporation | Treatment of lysosomal storage diseases |
| AU2008245578A1 (en) | 2007-04-26 | 2008-11-06 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| EP2252288A1 (en) | 2007-11-21 | 2010-11-24 | Summit Corporation Plc | Treatment of protein folding disorders |
| WO2009075815A1 (en) | 2007-12-07 | 2009-06-18 | Duke University | Immunomodulating gene therapy |
| PL3470077T3 (pl) | 2008-02-12 | 2021-04-06 | Amicus Therapeutics, Inc. | Sposób przewidywania odpowiedzi na leczenie chorób chaperonami farmakologicznymi |
| WO2009114679A2 (en) | 2008-03-12 | 2009-09-17 | Amicus Therapeutics, Inc | Treatment of pompe disease with specific pharmacological chaperones and monitoring treatment using surrogate markers |
| AU2009223125A1 (en) | 2008-03-12 | 2009-09-17 | Amicus Therapeutics, Inc. | Assays for diagnosing and evaluating treatment options for Pompe disease |
| PT2279210T (pt) * | 2008-05-07 | 2017-07-10 | Biomarin Pharm Inc | Péptidos de direcionamento lisossomal e suas utilizações |
| EP2323652A2 (en) | 2008-08-06 | 2011-05-25 | Summit Corporation Plc | Treatment of lysosomal storage disorders and other proteostatic diseases |
| WO2010056746A1 (en) | 2008-11-11 | 2010-05-20 | Amicus Therapeutics, Inc. | Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease |
| ES2735023T3 (es) * | 2008-12-16 | 2019-12-13 | Genzyme Corp | Intermedios sintéticos para preparar conjugados de oligosacáridos-proteínas |
| WO2010096369A1 (en) * | 2009-02-18 | 2010-08-26 | Amicus Therapeutics, Inc. | Mouse model for pompe disease and methods of use thereof |
| NZ595629A (en) | 2009-04-09 | 2013-04-26 | Amicus Therapeutics Inc | Methods for preventing and/or treating lysosomal storage disorders |
| ES2758827T3 (es) | 2009-06-17 | 2020-05-06 | Biomarin Pharm Inc | Formulaciones para enzimas lisosómicas |
| JP5415170B2 (ja) | 2009-07-21 | 2014-02-12 | 富士フイルム株式会社 | 複眼撮像装置 |
| CN102712914A (zh) * | 2009-09-29 | 2012-10-03 | 根特大学 | 水解甘露糖-1-磷酸-6-甘露糖连接为磷酸-6-甘露糖 |
| WO2011109600A1 (en) | 2010-03-05 | 2011-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for modifying the glycosylation pattern of a polypeptide |
| CN103328646B (zh) * | 2010-09-29 | 2021-06-18 | 奥克西雷恩英国有限公司 | 能够使甘露糖-1-磷酸-6-甘露糖连接脱帽并使磷酸化的n-聚糖脱甘露糖基化的甘露糖苷酶及促进糖蛋白的哺乳动物细胞摄取的方法 |
| SG10201605874TA (en) | 2011-04-22 | 2016-09-29 | Genzyme Corp | Modified acid alpha glucosidase with accelerated processing |
| BR112013030432A2 (pt) * | 2011-05-27 | 2016-12-13 | Callidus Biopharma Inc | método para preparar um peptídeo conjugado alvo para uma enzima lisossomal recombinante, método para preparar uma molécula para terapia de reposição de enzima, conjugado, método para tratar um indivíduo sofrendo de uma doença de armazenamento lisossomal, método para tratar um indivíduo sofrendo de uma doença de armazenamento lisossomal, método para tratar um paciente sofrendo da doença de pompe, doença de fabry, e doença de gaucher, mps i, mps ii, mps vii, tay sachs, sandhoff, alfa-manosidose, e wohlman, sequência de dna e sequência de aminoácidos |
| WO2013013017A2 (en) * | 2011-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics |
| WO2013016249A2 (en) * | 2011-07-22 | 2013-01-31 | Insight Photonic Solutions, Inc. | System and method of dynamic and adaptive creation of a wavelength-continuous and prescribed wavelength versus time sweep from a laser |
| BR112014014808A2 (pt) | 2011-12-22 | 2018-09-25 | Centogene Ip Gmbh | combinações de um composto que tem a capacidade de reorganizar uma enzima lisossômica e ambroxol e/ou um derivado de ambroxol, sua utilização, preparação farmacêutica e seu método de preparação |
| US9404100B2 (en) | 2012-03-07 | 2016-08-02 | Amicus Therapeutics, Inc. | High concentration alpha-glucosidase compositions for the treatment of Pompe disease |
| HRP20210398T1 (hr) | 2012-05-03 | 2021-05-28 | Amicus Therapeutics, Inc. | Režimi doziranja za liječenje pompeove bolesti |
| CA2915127A1 (en) | 2012-06-06 | 2013-12-12 | Giancarlo PARENTI | Allosteric chaperones and uses thereof |
| TWI529396B (zh) | 2014-07-18 | 2016-04-11 | Mpi Corp | Probe card and its transfer circuit board and signal feed structure |
| ES2967620T3 (es) | 2014-09-30 | 2024-05-03 | Amicus Therapeutics Inc | Alfa-glucosidasa ácida altamente potente con carbohidratos potenciados |
-
2015
- 2015-09-30 ES ES15845664T patent/ES2967620T3/es active Active
- 2015-09-30 SI SI201532053T patent/SI4273241T1/sl unknown
- 2015-09-30 DK DK15845664.0T patent/DK3201320T5/da active
- 2015-09-30 SI SI201531983T patent/SI3201320T1/sl unknown
- 2015-09-30 RS RS20240027A patent/RS65066B1/sr unknown
- 2015-09-30 HR HRP20250058TT patent/HRP20250058T1/hr unknown
- 2015-09-30 CN CN201580052512.5A patent/CN107075468B/zh active Active
- 2015-09-30 CA CA2961762A patent/CA2961762C/en active Active
- 2015-09-30 PE PE2017000507A patent/PE20170906A1/es unknown
- 2015-09-30 WO PCT/US2015/053252 patent/WO2016054231A1/en not_active Ceased
- 2015-09-30 AU AU2015325028A patent/AU2015325028B2/en active Active
- 2015-09-30 SM SM20240010T patent/SMT202400010T1/it unknown
- 2015-09-30 EP EP15845664.0A patent/EP3201320B1/en active Active
- 2015-09-30 FI FIEP15845664.0T patent/FI3201320T3/fi active
- 2015-09-30 LT LTEP23191307.0T patent/LT4273241T/lt unknown
- 2015-09-30 CR CR20170107A patent/CR20170107A/es unknown
- 2015-09-30 SM SM20250074T patent/SMT202500074T1/it unknown
- 2015-09-30 JP JP2017516917A patent/JP6851964B2/ja active Active
- 2015-09-30 US US15/515,808 patent/US10208299B2/en active Active
- 2015-09-30 SG SG10202003753PA patent/SG10202003753PA/en unknown
- 2015-09-30 BR BR112017005810A patent/BR112017005810A2/pt not_active Application Discontinuation
- 2015-09-30 EP EP23191307.0A patent/EP4273241B1/en active Active
- 2015-09-30 PL PL23191307.0T patent/PL4273241T3/pl unknown
- 2015-09-30 IL IL289383A patent/IL289383B2/en unknown
- 2015-09-30 DK DK23191307.0T patent/DK4273241T3/da active
- 2015-09-30 HU HUE23191307A patent/HUE070443T2/hu unknown
- 2015-09-30 SG SG11201702114TA patent/SG11201702114TA/en unknown
- 2015-09-30 HR HRP20240041TT patent/HRP20240041T1/hr unknown
- 2015-09-30 TN TN2017000082A patent/TN2017000082A1/en unknown
- 2015-09-30 CA CA3228032A patent/CA3228032A1/en active Pending
- 2015-09-30 EA EA201790724A patent/EA038986B1/ru unknown
- 2015-09-30 LT LTEPPCT/US2015/053252T patent/LT3201320T/lt unknown
- 2015-09-30 PT PT158456640T patent/PT3201320T/pt unknown
- 2015-09-30 KR KR1020217030450A patent/KR102455814B1/ko active Active
- 2015-09-30 IL IL307587A patent/IL307587A/en unknown
- 2015-09-30 KR KR1020247040492A patent/KR20250004926A/ko active Pending
- 2015-09-30 HU HUE15845664A patent/HUE064629T2/hu unknown
- 2015-09-30 EP EP24197546.5A patent/EP4455283A3/en active Pending
- 2015-09-30 KR KR1020227035610A patent/KR102741048B1/ko active Active
- 2015-09-30 PT PT231913070T patent/PT4273241T/pt unknown
- 2015-09-30 MX MX2017003989A patent/MX388241B/es unknown
- 2015-09-30 PL PL15845664.0T patent/PL3201320T3/pl unknown
- 2015-09-30 CN CN202111483006.5A patent/CN114540327A/zh active Pending
- 2015-09-30 MY MYPI2017000365A patent/MY186336A/en unknown
- 2015-09-30 FI FIEP23191307.0T patent/FI4273241T3/fi active
- 2015-09-30 KR KR1020177011346A patent/KR102306577B1/ko active Active
- 2015-09-30 RS RS20250154A patent/RS66510B1/sr unknown
- 2015-09-30 ES ES23191307T patent/ES3017134T3/es active Active
-
2017
- 2017-03-10 PH PH12017500455A patent/PH12017500455A1/en unknown
- 2017-03-14 IL IL251152A patent/IL251152B/en active IP Right Grant
- 2017-03-20 DO DO2017000079A patent/DOP2017000079A/es unknown
- 2017-03-20 ZA ZA2017/01945A patent/ZA201701945B/en unknown
- 2017-03-23 CO CONC2017/0002776A patent/CO2017002776A2/es unknown
- 2017-03-27 MX MX2021014565A patent/MX2021014565A/es unknown
- 2017-03-27 CL CL2017000722A patent/CL2017000722A1/es unknown
- 2017-03-28 SV SV2017005416A patent/SV2017005416A/es unknown
- 2017-03-28 NI NI201700039A patent/NI201700039A/es unknown
- 2017-03-28 EC ECIEPI201719103A patent/ECSP17019103A/es unknown
-
2019
- 2019-01-18 US US16/252,505 patent/US10961522B2/en active Active
- 2019-03-19 ZA ZA2019/01690A patent/ZA201901690B/en unknown
-
2020
- 2020-09-23 IL IL277529A patent/IL277529B/en unknown
- 2020-09-25 JP JP2020161470A patent/JP7225176B2/ja active Active
-
2021
- 2021-02-23 US US17/249,175 patent/US11753632B2/en active Active
-
2022
- 2022-02-04 US US17/665,179 patent/US11591583B2/en active Active
- 2022-05-24 AU AU2022203498A patent/AU2022203498B2/en active Active
-
2023
- 2023-02-08 JP JP2023017964A patent/JP2023078118A/ja active Pending
- 2023-02-17 US US18/111,321 patent/US20230203465A1/en active Pending
-
2024
- 2024-01-10 CY CY20241100016T patent/CY1126544T1/el unknown
- 2024-03-28 FR FR24C1012C patent/FR24C1012I1/fr active Active
- 2024-04-02 CY CY2024009C patent/CY2024009I1/el unknown
- 2024-04-02 LT LTPA2024509C patent/LTPA2024509I1/lt unknown
- 2024-04-02 HU HUS2400007C patent/HUS2400007I1/hu unknown
- 2024-04-03 FI FIC20240010C patent/FIC20240010I1/fi unknown
-
2025
- 2025-01-17 US US19/028,827 patent/US20260015600A1/en active Pending
- 2025-02-17 AU AU2025201108A patent/AU2025201108A1/en active Pending
- 2025-05-21 FI FIC20250020C patent/FIC20250020I1/fi unknown
- 2025-05-23 FR FR25C1019C patent/FR25C1019I1/fr active Active
- 2025-05-23 NO NO2025023C patent/NO2025023I1/no unknown
- 2025-06-02 LT LTPA2025521C patent/LTPA2025521I1/lt unknown
- 2025-06-03 HU HUS2500025C patent/HUS2500025I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170906A1 (es) | Alfa-glucosidasa acida muy potente con hidratos de carbono potenciados | |
| MX2020006117A (es) | Integracion dirigida de acidos nucleicos. | |
| MY187542A (en) | Carbohydrate degrading polypeptide and uses thereof | |
| AR090973A1 (es) | Anticuerpos utiles para el diagnostico del cancer | |
| BR112015013525A2 (pt) | método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão | |
| PE20170908A1 (es) | VARIANTES DE INTERFERON a2b | |
| MX2017010880A (es) | Variantes de polipéptidos para el clivaje de la toxina fusario, aditivo que contiene las mismas, uso de las mismas, y método para el clivaje de las toxinas fusario. | |
| AR092712A1 (es) | Una proteina con actividad cetosa 3-epimerasa | |
| BR112013032717A2 (pt) | coagonistas do receptor de glucagon/glp-1 | |
| BR112015027567A2 (pt) | polipeptídeo, sequência de ácido nucleico isolada, célula, método de fornecimento de uma imunidade antitumoral | |
| MY175708A (en) | Dna antibody constructs and method of using same | |
| EA201101553A1 (ru) | Полипептид, деградирующий углеводы, и его применения | |
| BR112012033404A2 (pt) | polipetídeo tendo ou auxiliando a atividade de degradação de material de carboidratos e uso dos mesmos. | |
| BR112012033699A2 (pt) | polipeptídeo tendo atividade beta-glicosidase e seus usos | |
| AR100606A1 (es) | Variantes de lipasas y polinucleótidos que las codifican | |
| MX2023009421A (es) | Construcciones de anticuerpos de adn y metodo para utilizarlas. | |
| MX383531B (es) | Novedoso bacteriófago clo-pep-1 de clostridium perfringens y su uso para inhibir la proliferación de clostridium perfringens | |
| GT201300252A (es) | Alfa glucosidasa ácida modificada con procesamiento acelerado | |
| PE20180128A1 (es) | Compuestos antisenescentes y usos de los mismos | |
| MX386450B (es) | Microorganismo recombinante para la producción mejorada de productos químicos finos. | |
| MX2017016610A (es) | Metodos de reduccion de olor. | |
| BR112016016539A2 (pt) | micro-organismos recombinantes enriquecidos com carboidratos | |
| EA201300056A1 (ru) | Полипептид с активностью ацетилксиланэстеразы и его применения | |
| AR102445A1 (es) | COMPOSICIONES Y MÉTODOS RELACIONADOS CON b-GLUCOSIDASA | |
| MX382218B (es) | Variantes de lipasa y polinucleotidos que las codifican. |